Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated Infusion Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT03697629Phase 2Completed
- Sponsor
- Canadian Myeloma Research Group
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Canadian Myeloma Research Group. Started Dec 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03697629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697629.